Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Revenue projections:

Revenue projections for JUBLPHARMA
Revenue projections for JUBLPHARMA

Investors are expected to be cautious with Jubilant Pharmova Limited, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 1.653000
forwardPE 24.850622
debtToEquity 43.776000
earningsGrowth 0.000000
revenueGrowth 0.097000
grossMargins 0.679730
operatingMargins 0.129720
trailingEps 52.900000
forwardEps 0.000000

JUBLPHARMA's current ratio of 1.653 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. JUBLPHARMA's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
Jubilant Pharmova Limited's Forward PE is in a favorable range, suggesting the stock is reasonably priced relative to its earnings. This indicates the stock is not overpriced, providing room for potential growth and making it an attractive option for investors looking for solid value and future upside.

Price projections:

Price projections for JUBLPHARMA
Price projections for JUBLPHARMA

The current valuation of Jubilant Pharmova Limited against its projections does not reveal significant risks or opportunities. This neutral assessment implies a stable market, where investors may prefer to maintain their positions until future trends become clearer.

Insider Transactions:

Insider Transactions for JUBLPHARMA
Insider Transactions for JUBLPHARMA


Jubilant Pharmova Limited stock was bought in 1 transactions, while the market price was at 1219.5999755859375.There were no buy transactions during the given period.Jubilant Pharmova Limited has seen more sells at current price levels, which could indicate a potential decline. If this trend continues, investors may expect the stock's price to drop further as more people exit their positions.

Recommendation changes over time:

Recommendations trend for JUBLPHARMA
Recommendations trend for JUBLPHARMA


JUBLPHARMA has garnered a buy bias from analysts recently, suggesting the stock is a good investment opportunity. This may lead to increased investor interest, as JUBLPHARMA is seen as a reliable place to park money for those looking to benefit from potential market gains and company growth.